- Home
- CAPR vs GAMB Comparison
CAPR vs GAMB Comparison
Compare CAPR & GAMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- GAMB
- Stock Information
- Founded
- CAPR 2005
- GAMB 2006
- Country
- CAPR United States
- GAMB Jersey
- Employees
- CAPR N/A
- GAMB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- GAMB Services-Misc. Amusement & Recreation
- Sector
- CAPR Health Care
- GAMB Consumer Discretionary
- Exchange
- CAPR Nasdaq
- GAMB Nasdaq
- Market Cap
- CAPR 324.6M
- GAMB 273.9M
- IPO Year
- CAPR N/A
- GAMB 2021
- Fundamental
- Price
- CAPR $6.18
- GAMB $7.48
- Analyst Decision
- CAPR Strong Buy
- GAMB Strong Buy
- Analyst Count
- CAPR 6
- GAMB 8
- Target Price
- CAPR $23.00
- GAMB $15.13
- AVG Volume (30 Days)
- CAPR 1.0M
- GAMB 719.7K
- Earning Date
- CAPR 11-12-2025
- GAMB 11-13-2025
- Dividend Yield
- CAPR N/A
- GAMB N/A
- EPS Growth
- CAPR N/A
- GAMB N/A
- EPS
- CAPR N/A
- GAMB 0.40
- Revenue
- CAPR $13,392,150.00
- GAMB $147,655,000.00
- Revenue This Year
- CAPR N/A
- GAMB $38.41
- Revenue Next Year
- CAPR $7,894.07
- GAMB $11.58
- P/E Ratio
- CAPR N/A
- GAMB $18.88
- Revenue Growth
- CAPR N/A
- GAMB 27.57
- 52 Week Low
- CAPR $5.68
- GAMB $7.36
- 52 Week High
- CAPR $22.90
- GAMB $17.14
- Technical
- Relative Strength Index (RSI)
- CAPR 40.96
- GAMB 37.92
- Support Level
- CAPR $6.05
- GAMB $7.55
- Resistance Level
- CAPR $6.42
- GAMB $7.84
- Average True Range (ATR)
- CAPR 0.34
- GAMB 0.29
- MACD
- CAPR -0.07
- GAMB 0.02
- Stochastic Oscillator
- CAPR 8.95
- GAMB 17.09
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.